Literature DB >> 20877538

A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Jason J Emer1, Amylynne Frankel, Joshua A Zeichner.   

Abstract

Psoriasis is a chronic, systemic, inflammatory skin condition that manifests predominantly as well-demarcated, erythematous, scaly plaques on the elbows, knees, and scalp. While mild cases (minimal body surface) often respond to various topical treatments and light therapy, patients with extensive disease (larger body surface and possibly joint involvement) may require systemic medications for remission. The development of biological agents provides dermatologists valuable ways to help treat psoriatic disease quite efficiently, but literature regarding the monitoring of patients on biological treatments is sparse. Clinical practice varies widely since there is modest strong evidence to recommend or refute most tests currently recommended by the United States Food and Drug Administration. The purpose of this article is to present a practical approach to monitoring patients on biological therapy based on the most up-to-date literature.

Entities:  

Year:  2010        PMID: 20877538      PMCID: PMC2945861     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  75 in total

1.  Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.

Authors:  A W A M van Rijthoven; J W J Bijlsma; M Canninga-van Dijk; R H W M Derksen; J A G van Roon
Journal:  Rheumatology (Oxford)       Date:  2006-07-13       Impact factor: 7.580

2.  Adalimumab-associated multiple sclerosis.

Authors:  Lamiae Bensouda-Grimaldi; Denis Mulleman; Jean-Pierre Valat; Elisabeth Autret-Leca
Journal:  J Rheumatol       Date:  2007-01       Impact factor: 4.666

3.  Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.

Authors:  Pilar Martinez Montiel; Jose Antonio Solis; Juan Antonio Chirinos; Begoń a Casis; Fernando Sánchez; Sarbelio Rodríguez
Journal:  Liver Int       Date:  2008-05       Impact factor: 5.828

4.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

5.  Etanercept and demyelinating disease in a patient with psoriasis.

Authors:  Sean A Sukal; Lakshmi Nadiminti; Richard D Granstein
Journal:  J Am Acad Dermatol       Date:  2006-01       Impact factor: 11.527

6.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

7.  Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

Review 8.  Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.

Authors:  Andrea Duchini; John A Goss; Saul Karpen; Paul J Pockros
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Etanercept therapy in patients with a positive tuberculin skin test.

Authors:  A M Manadan; K Joyce; W Sequeira; J A Block
Journal:  Clin Exp Rheumatol       Date:  2007 Sep-Oct       Impact factor: 4.473

10.  Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice.

Authors:  N Cassano; V Mastrandrea; R Buquicchio; A Miracapillo; F Loconsole; R Filotico; G A Vena
Journal:  J Biol Regul Homeost Agents       Date:  2008 Jul-Sep       Impact factor: 1.711

View more
  4 in total

1.  Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Authors:  Laura Niccoli; Carlotta Nannini; Corrado Blandizzi; Stefania Mantarro; Marta Mosca; Ombretta Di Munno; Delia Goletti; Maurizio Benucci; Francesca Li Gobbi; Emanuele Cassarà; Olga Kaloudi; Fabrizio Cantini
Journal:  Ther Clin Risk Manag       Date:  2018-10-24       Impact factor: 2.423

2.  Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.

Authors:  Mayara Costa de Camargo; Bruna Cipriano Almeida Barros; Izabela Fulone; Marcus Tolentino Silva; Miriam Sanches do Nascimento Silveira; Iara Alves de Camargo; Silvio Barberato-Filho; Fernando de Sá Del Fiol; Luciane Cruz Lopes
Journal:  Front Pharmacol       Date:  2019-09-11       Impact factor: 5.810

3.  Gaps in moderate plaque psoriasis management: A survey of Saudi dermatologists.

Authors:  Mohammad Almohideb; Nora Abdulrahman Almohideb
Journal:  J Family Med Prim Care       Date:  2021-12-27

Review 4.  Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.

Authors:  Yi-Hsing Chen; Hellen Mds de Carvalho; Umut Kalyoncu; Lyndon John Q Llamado; Gaston Solano; Ron Pedersen; Galina Lukina; Juan J Lichauco; Radu S Vasilescu
Journal:  Biologics       Date:  2018-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.